Abstract: Objective To systematically evaluate the clinical efficacy of Guanxinping on coronary heart disease(CHD),and provide evidence-based medicine basis for clinical medication. Methods The related literatures were searched in databases such as Chinese National Knowledge Infrastructure (CNKI), Cochrane Library, VIP, Embase, Wanfang database, China Biology Medicine (CBM),PubMed. The time limit was from the establishment of the database to June 2022.Two researchers independently selected literatures based on the inclusion criteria, and collected randomized controlled trials(RCT) and case-control studies of Guanxinping(the experimental group). After screening the literatures and extracting the data, the quality of RCTs were evaluated by the bias risk assessment tool recommended by Cochrane System Reviewer Manual 5.1.0. A Meta-analysis was performed by RevMan 5.3 and Stata 15.0. A trial sequential analysis was performed by TSA 0.9, and publication bias assessment was performed by Stata 15.0. Results A total of 25 studies were included, with a total sample of 1968 cases. The Meta-analysis results showed that the comprehensive clinical effect (OR=2.78,95%CI:2.11-3.68)、electrocardiogram curative effect (OR=2.63,95%CI:2.01-3.45) and traditional Chinese medicine(TCM) syndrome curative effect (OR=3.27,95%CI:2.29-4.66) of Guanxinping on CHD were significantly better than those in the control group. The sequential analysis of trials showed that the clinical total efficiency of Guanxinping on CHD was confirmed. Conclusions The clinical efficacy of Guanxinping on CHD is significant, and has potential value of clinical application.

Key words: Guanxinping, coronary heart disease, Meta-analysis, trial sequential analysis